Skip to main content

Phase I Study of Fractionated Stereotactic Radiation Therapy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Phase I Study of Fractionated Stereotactic Radiation Therapy

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Family Groups for Urban Youth With Disruptive Behavior

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Family Groups for Urban Youth With Disruptive Behavior

S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

Understanding the Pathophysiology of Migraine Pain

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Understanding the Pathophysiology of Migraine Pain

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 234
  • Page 235
  • Page 236
  • Page 237
  • Page 238
  • Page 239
  • Page 240
  • Page 241
  • Page 242
  • …
  • Next page Next
  • Last page Last
Subscribe to